| Literature DB >> 30967586 |
Cameron J Fairfield1, Stephen J Wigmore2, Ewen M Harrison2.
Abstract
Gallstone disease (GD) is one of the most common presentations to surgical units worldwide and shares several risk factors with cardiovascular disease (CVD). CVD remains the most common cause of death worldwide and results in considerable economic burden. Recent observational studies have demonstrated an association between GD and CVD with some studies demonstrating a stronger association with cholecystectomy. We present the findings of a meta-analysis assessing the relationship between GD and CVD. A total of fourteen cohort studies with over 1.2 million participants were included. The pooled hazard ratio (HR, 95% confidence interval [CI]) for association with GD from a random-effects model is 1.23 (95%CI: 1.16-1.30) for fatal and non-fatal CVD events. The association was present in females and males. Three studies report the relationship between cholecystectomy and CVD with a pooled HR of 1.41 (95%CI: 1.21-1.64) which compares to a HR of 1.30 (95%CI: 1.07-1.58) when cholecystectomy is excluded although confounding may influence this result. Our meta-analysis demonstrates a significant relationship between GD and CVD events which is present in both sexes. Further research is needed to assess the influence of cholecystectomy on this association.Entities:
Mesh:
Year: 2019 PMID: 30967586 PMCID: PMC6456597 DOI: 10.1038/s41598-019-42327-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flow chart of study selection process
Characteristics of Included Studies.
| Author | Paul | Petitti | Bortnichak | Bortnichak | Grimaldi | Ruhl | Olaiya | Wei | Lv | Wirth | Zheng | Zheng | Zheng | Shabanzdeh |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year | 1963 | 1979 | 1985 | 1985 | 1993 | 2011 | 2013 | 2014 | 2015 | 2015 | 2016 | 2016 | 2016 | 2017 |
| Sex | Male | Female | Male | Female | Both | Both | Both | Both | Both | Both | Female | Female | Male | Both |
| Country | United States | United States | United States | United States | United States | United States | Taiwan | Taiwan | China | Germany | United States | United States | United States | Denmark |
| Design | Prospective cohort | Prospective cohort | Prospective cohort | Prospective cohort | Prospective cohort | Prospective cohort | Retrospective cohort | Retrospective cohort | Prospective cohort | Prospective cohort | Prospective cohort | Prospective cohort | Prospective cohort | Prospective cohort |
| Case ascertainment | Employees of WEC | WCCDS | FHS | FHS | GRIC | NHANES | NHIRD | NHIRD | CKB | EPIC-Germany | NHS | NHSII | HPFS | MONICA - Danish |
| GD diagnosis | Not stated | Not stated | Baseline US | Baseline US | Cholecystography | Baseline US | Inpatient insurance claims for GD | Inpatient HR | Self-reported GD at baseline | Self-reported GD at baseline | Self-reported GD at baseline | Self-reported GD at baseline | Self-reported GD at baseline | Baseline US |
| CVD diagnosis | Planned follow-up examination | Self-reported outcome verified in HR | HR | HR | Review of DC | Review of DC | National database linkage (ICD-9) | National database linkage (ICD-9) | Linkage to DC registry and insurance registry, active follow-up, verification of HR and DC by cardiologist | Postal questionnaire, HR or DC | HR and DC | HR and DC | HR and DC | National database linkage (ICD8 and ICD10) |
| CVD definition | CHD | CHD, cerebro-vascular disease, VTE | CHD, coronary insufficiency, sudden death, (not angina pectoris) | CHD, coronary insufficiency, sudden death, (not angina pectoris) | Death due to CVD | Death due to CVD | CHD, cerebrovascular disease, coronary insufficiency | Cerebrovascular disease | CHD | CHD, cerebrovascular disease | CHD | CHD | CHD | CHD, cerebro-vascular disease, VTE |
| No. Cases | Not stated | Not stated | 180* | 322* | 222 | 2018 | 6981 | 135512 | 28345 | 4828 | 8796 | 5227 | 1449 | 504 |
| No. Control | Not stated | Not stated | 2028 | 2178 | 161 | 12210 | 27924 | 271024 | 459028 | 41658 | 103724 | 107692 | 42252 | 4992 |
| Follow-up (years) | 4.5 | 6.5 | 26 | 26 | 20 | 14.7 | 6 | 7–10 | 7.2 | 8.2 | 30 | 22 | 25 | 32 |
| Con-founder adjust-ment | Not stated | Smoking, age, obesity, current OC use, previous OC use, hypertension, hypercholesterolaemia, alcohol consumption | Age, smoking, obesity, hypertension, hypercholesterolaemia, diabetes mellitus, LVH | Age, smoking, obesity, hypertension, hypercholesterolaemia, diabetes mellitus, LVH | Age, sex, diabetes mellitus, BMI, serum cholesterol | Age, sex, ethnicity, education, BMI, WHR, diabetes mellitus, HbA1c > 6.5%, serum cholesterol, smoking, alcohol consumption, caffeine consumption, CRP protein, SBP, DBP | Age, sex, PVD, hyperlipidaemia, diabetes mellitus, hypertension, COPD, alcoholism, CLD, HHA, AHA | Age, sex, hypertension, diabetes mellitus, IHD, AF, hyperlipidaemia | Age, sex, education, marital status, alcohol consumption, smoking, physical activity, red meat intake, fruit intake, vegetable intake, hypertension, diabetes mellitus, family history IHD, menopausal status, BMI, chronic hepatitis, cirrhosis, PUD | Age, sex, study centre, educational achievement, physical activity, smoking, alcohol intake, BMI, waist circumference, hypertension, hyperlipidaemia | Age, ethnicity, family history IHD, marital status, smoking, BMI, physical activity, diabetes mellitus, hypertension, hyperchole-sterolaemia, aspirin-use, alcohol intake, energy-adjusted cholesterol-intake, energy intake, menopausal status, HRT, OC use | Age, ethnicity, family history IHD, marital status, smoking, BMI, physical activity, diabetes mellitus, hypertension, hyperchole-sterolaemia, aspirin-use, alcohol intake, energy-adjusted cholesterol-intake, energy intake, menopausal status, HRT, OC use | Age, ethnicity, family history IHD, marital status, smoking, BMI, physical activity, diabetes mellitus, hypertension, hyperchole-sterolaemia, aspirin-use, alcohol intake, energy-adjusted cholesterol-intake, energy intake | Age, sex, cohort, BMI, SBP, DBP, non-HDL cholesterol, HDL, smoking, alcohol consumption, diet, physical activity, social group |
| Quality assessment (NOS) | Selection: 2 Comp-arability: 0 Outcome: 2 | Selection: 2 Comp-arability: 1 Outcome: 2 | Selection: 3 Comparability: 2 Outcome: 3 | Selection: 3 Comp-arability: 2 Outcome: 3 | Selection: 2 Comp-arability: 1 Outcome: 3 | Selection: 3 Comp-arability: 2 Outcome: 3 | Selection: 4 Comparability: 2 Outcome: 1 | Selection: 4 Comparability: 1 Outcome: 1 | Selection: 4 Comparability: 1 Outcome: 2 | Selection: 2 Comparability: 2 Outcome: 1 | Selection: 3 Comparability: 2 Outcome: 2 | Selection: 3 Comparability: 2 Outcome: 2 | Selection: 3 Comp-arability: 2 Outcome: 2 | Selection: 4 Comp-arability: 2 Outcome: 3 |
GD: gallstone disease; CVD: cardiovascular disease; NOS: Newcastle-Ottawa Scale; US: ultrasound; WEC: Hawthorne Works of the Western Electrical Company (Chicago); WCCDS: Walnut Creek Contraceptive Drug Study; FHS: Framingham Heart Study; GRIC: Gila River Indian Community; NHANES: National Health and Nutrition Examination Survey; NHIRD: National Health Insurance Research Database; CKD: China Kadoorie Biobank; EPIC-Germany: European Prospective Investigation into Cancer and Nutrition, German cohorts; NHS: Nurses’ Health Study; NHSII: Nurses’ Health Study II; HPFS: Health Professionals Follow-up Study; MONICA: Multinational mONItoring of trends and determinants in CArdiovascular disease, Danish cohorts only), HR: hospital records; DC: death certificates; ICD-9-CM: International Classification of Diseases, 9th Revision, Clinical Modification; IHD: ischaemic heart disease; VTE: venous thromboembolism; MI: myocardial infarction; PVD: peripheral vascular disease; OC: oral contraceptive; LVH: left ventricular hypertrophy; BMI: body mass index; WHR: waist-to-hip ratio; CRP: C-reactive protein; SBP: systolic blood pressure; DBP: diastolic blood pressure; COPD: chronic obstructive pulmonary disease; CLD: chronic liver disease; HHA: hereditary haemolytic anaemia; AHA: acquired haemolytic anaemia; AF: atrial fibrillation; PUD: peptic ulcer disease; HRT: hormone-replacement therapy without cholecystectomy excluded from analysis, number of cases remaining in analysis not stated.
Figure 2Forest plot demonstrating relationship between GD and CVD. Squares and horizontal lines represent individual studies with 95% confidence intervals. Area of squares is proportional to study weighting in random effects meta-analysis. Diamond (blue) represents pooled HR from meta-analysis with 95% CI. Reference line (black) represents hazard ratio of 1.00 (no association between GD and CVD). Summary line (red) represents summary estimate and demonstrates increased risk of CVD with GD (23%).
Subgroup Analyses for relationship between GD and CVD.
| Subgroup | HR (95% CI) | P (Cochran Q test) | I2 | P (Wald-type test) | Studies |
|---|---|---|---|---|---|
| Sex | |||||
| Female | 1.24 (1.17–1.32) | 0.000 | 77.9% | 0.428 | 5* |
| Male | 1.18 (1.04–1.33) | 0.000 | 90.5% | 4* | |
| Diabetes | |||||
| Diabetic | 1.13 (1.06–1.20) | NA | NA | 0.075 | 1 |
| Non-diabetic | 1.23 (1.15–1.32) | 0.000 | 91.3% | 6** | |
| Detection of GD | |||||
| Screen-detected | 1.35 (1.17–1.57) | 0.847 | 0.00% | 0.183 | 2 |
| Symptomatic | 1.21 (1.15–1.29) | 0.000 | 82.4% | 6* | |
Studies which included duplicated participants report subgroup results for male and female participants and symptomatic GD, we therefore conducted two separate analyses which produced similar results. studies reported in one publication are pooled by meta-analysis and both studies which included duplicated participants report subgroup analyses for non-diabetic participants and we therefore conducted four separate analyses (with and without inclusion of the pooled result and with and without each study using duplicated participants) which produced similar results.
Figure 3Forest plot demonstrating relationship between GD and CVD stratified by sex. Blue diamonds represent pooled summary estimate with 95% CI for each subgroup and overall pooled estimate for both groups combined.
Figure 4Funnel plot with pseudo-95% confidence limits. Circles represent identified studies. Log-transformed adjusted HR plotted against inverse standard error of log-transformed HR.